Table 6.

Therapeutic Strategies Being Investigated in the Treatment of Acute Myeloid Leukemia (AML)

Therapeutic approach	Examples
Epigenetic regulation	Histone deacetylase inhibitors: vorinostat, panobinostat, belinostat DNA methyl transferase inhibitors: Vidaza, Dacogen
Differentiation-inducing therapeutics	Retinoid X receptor agonists Arsenic trioxide
Angiogenesis inhibition	Inhibition of angiogenesis: Velcade Thalomid, Revlimid
Inhibition of signaling pathways	Tyrosine kinase inhibitors: midostaurin, lestaurtinib, sorafenib, KW-2449, AC220 Cell cycle inhibitors: ON 01910.Na Farnesyl transferase inhibitors: Zarnestra, Sarasar mTOR inhibitors: Afinitor, PI-103, temsirolimus, GSK21110183 PARP inhibitors: ABT-888 MEK1/2 inhibitors: AZD6244, AS703026, PD98059, GSK1120212 Bcl-2 inhibitors: oblimersen, obatoclax, ABT-263 XIAP inhibitor: AEG-35156 Aminopeptidase inhibitors (tosedostat)
Modulation of drug resistance	Valspodar, zosuquidar
Modified traditional chemotherapeutics	Nucleoside analogs: clofarabine, sapacitabine, elacytarabine Alkylating drugs: irofulven, Temodar, Onrigin Topoisomerase inhibitors: Hycamtin
Immune therapy	Antibodies: Mylotarg, lintuzumab, Avastin, T-cell targeted therapy